The "Hidden" Reasons Psychiatric Drug Development Programs Fail After Phase I

A successful Phase I study does not guarantee that a psychiatric drug is positioned for later-stage success. Acceptable safety and predictable pharmacokinetics may support continued development, but they reveal little about whether the selected dose engages the intended CNS mechanism or will benefit the target patient population. Variability in drug exposure and target sensitivity can further complicate dose selection, allowing group averages to conceal meaningful differences among participants.
Biomarker strategy introduces another critical risk. A pharmacodynamic response may confirm that a drug has biological activity without demonstrating that the activity is connected to the disease process or clinically meaningful outcomes. Even a relevant mechanism may fail to produce efficacy when symptom-based diagnoses include patients with distinct underlying biology.
A staged evidence strategy can expose these hidden assumptions earlier by connecting exposure, target engagement, mechanism, patient biology, and clinical response. Explore how quantitative human pharmacology, carefully selected biomarkers, and early patient studies can strengthen dose selection, patient stratification, and later-phase trial design.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.